Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OPT Opthea	$3.41 +7.2%	$3.41	$1.79 ▼ $6.30	$524.84M	1.17	N/A	3,000 shs
PGEN Precigen	$1.67 -2.3%	$1.57	$0.65 ▼ $2.17	$504.76M	1.87	3.00 million shs	2.02 million shs
SLDB Solid Biosciences	$6.83 -0.1%	$5.06	$2.41 ▼ $10.37	$530.21M	2.43	1.46 million shs	1.15 million shs
SPRO Spero Therapeutics	$2.30 -0.9%	$2.59	$0.51 ▼ $3.22	$129.71M	1.39	770,756 shs	518,730 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+50.22%
PGEN Precigen	-2.34%	+6.37%	+3.73%	+6.37%	+9.87%
SLDB Solid Biosciences	-0.15%	-2.43%	+40.25%	+58.47%	-23.43%
SPRO Spero Therapeutics	-0.86%	-1.29%	-20.69%	+255.49%	+63.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OPT Opthea	0.3208 of 5 stars	1.1	0.0	0.0	1.5	0.8	0.6
PGEN Precigen	3.9761 of 5 stars	3.5	1.0	4.7	3.1	1.7	0.6
SLDB Solid Biosciences	2.6433 of 5 stars	4.6	1.0	0.0	1.1	1.7	0.6
SPRO Spero Therapeutics	3.7158 of 5 stars	3.3	5.0	4.7	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside
PGEN Precigen	3.00	Buy	$6.00	259.28% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	121.08% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	117.39% Upside

Current Analyst Ratings Breakdown

Latest SPRO, OPT, PGEN, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09
PGEN Precigen	$3.92M	125.75	N/A	N/A	$0.13 per share	12.85
SLDB Solid Biosciences	$8.09M	65.44	N/A	N/A	$3.43 per share	1.99
SPRO Spero Therapeutics	$47.98M	2.68	N/A	N/A	$0.85 per share	2.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)

Latest SPRO, OPT, PGEN, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PGEN Precigen	-$0.14	N/A	N/A	N/A	$0.67 million	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	SPRO Spero Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OPT Opthea	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OPT Opthea	N/A	1.57	N/A
PGEN Precigen	N/A	3.53	3.53
SLDB Solid Biosciences	N/A	10.89	10.89
SPRO Spero Therapeutics	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OPT Opthea	55.95%
PGEN Precigen	33.51%
SLDB Solid Biosciences	81.46%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
OPT Opthea	3.20%
PGEN Precigen	47.10%
SLDB Solid Biosciences	1.90%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable

SPRO, OPT, PGEN, and SLDB Headlines

Recent News About These Companies

Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025 | globenewswire.com

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

May 5, 2025 | globenewswire.com

Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 29, 2025 | finanznachrichten.de

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 28, 2025 | globenewswire.com

Spero Therapeutics Analyst Ratings

April 7, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Rocket Lab: A Parabolic Run Meets a Healthy Pullback
By Ryan Hasson | July 23, 2025
View Rocket Lab: A Parabolic Run Meets a Healthy Pullback
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
CSX Stock Rally: Strong Options Flow, Analyst Price Targets
By Jeffrey Neal Johnson | July 18, 2025
View CSX Stock Rally: Strong Options Flow, Analyst Price Targets
Palantir Bulls and Bears Set for an August Showdown
By Chris Markoch | July 22, 2025
View Palantir Bulls and Bears Set for an August Showdown

SPRO, OPT, PGEN, and SLDB Company Descriptions

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 07/31/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Precigen NASDAQ:PGEN

$1.67 -0.04 (-2.34%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.72 +0.05 (+2.93%)

As of 08/1/2025 07:59 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Solid Biosciences NASDAQ:SLDB

$6.83 -0.01 (-0.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.64 -0.19 (-2.71%)

As of 08/1/2025 06:33 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Spero Therapeutics NASDAQ:SPRO

$2.30 -0.02 (-0.86%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.31 +0.01 (+0.61%)

As of 08/1/2025 05:00 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time